KRAS and neoplasm: Notably, patients with mutant KRas cancers have poor prognosis, increased tumor aggressiveness and metastasis, and are less likely to respond to chemotherapy and targeted therapies3–6, leading the National Comprehensive Cancer Network to recommend treatment with epidermal growth factor (EGF) receptor inhibitors only in patients whose tumors harbor wild-type KRas4.